Literature DB >> 17100637

Inhibitors of the TGF-beta superfamily and their clinical applications.

K Tsuchida1, Y Sunada, S Noji, T Murakami, A Uezumi, M Nakatani.   

Abstract

The transforming growth factor-beta (TGF-beta) superfamily includes TGF-betas, activin, myostatin and bone morphogenetic proteins. Misregulation of the activity of TGF-beta family members is involved in pathogenesis of cancer, muscular dystrophy, obesity and bone and tooth remodeling. Natural inhibitors for the TGF-beta superfamily regulate fine-tuning of activity of TGF-beta family in vivo. In addition to natural inhibitors for the TGF-beta family, soluble forms of receptors for the TGF-beta family, blocking monoclonal antibodies and small chemical TGF-beta inhibitors have been developed. In this review, we summarize recent advances in our understanding of inhibitors for the TGF-beta superfamily and their medical applications.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17100637     DOI： 10.2174/138955706778742759

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN： 1389-5575            Impact factor:   3.862


  9 in total

1.  Adeno-associated virus-mediated expression of myostatin propeptide improves the growth of skeletal muscle and attenuates hyperglycemia in db/db mice.

Authors:  J G Jiang; G F Shen; J Li; C Qiao; B Xiao; H Yan; D W Wang; X Xiao
Journal:  Gene Ther       Date:  2016-12-16       Impact factor: 5.250

Review 2.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

3.  Increase in tumour permeability following TGF-beta type I receptor-inhibitor treatment observed by dynamic contrast-enhanced MRI.

Authors:  T Minowa; K Kawano; H Kuribayashi; K Shiraishi; T Sugino; Y Hattori; M Yokoyama; Y Maitani
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

Review 4.  Bone metastasis: pathogenesis and therapeutic implications.

Authors:  Philippe Clezardin; Anna Teti
Journal:  Clin Exp Metastasis       Date:  2007-11-16       Impact factor: 5.150

5.  Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice.

Authors:  K Tsuchida
Journal:  Acta Myol       Date:  2008-07

Review 6.  Promising molecular targets and biomarkers for male BPH and LUTS.

Authors:  Mehrnaz Gharaee-Kermani; Jill A Macoska
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

7.  TGFβ1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy.

Authors:  Xianglin Yuan; Qingyi Wei; Ritsuko Komaki; Zhensheng Liu; Ju Yang; Susan L Tucker; Ting Xu; John V Heymach; Charles Lu; James D Cox; Zhongxing Liao
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

8.  Glucocorticoids Enhance Muscle Proteolysis through a Myostatin-Dependent Pathway at the Early Stage.

Authors:  Ruxia Wang; Hongchao Jiao; Jingpeng Zhao; Xiaojuan Wang; Hai Lin
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

9.  Chamaejasmenin B, a novel candidate, inhibits breast tumor metastasis by rebalancing TGF-beta paradox.

Authors:  Qi Li; Yajie Wang; Hongbin Xiao; Yujie Li; Xiaoxi Kan; Xiaomin Wang; Ganlin Zhang; Zhixin Wang; Qing Yang; Xi Chen; Xiaogang Weng; Ying Chen; Bingbing Zhou; Yan Guo; Xucen Liu; Xiaoxin Zhu
Journal:  Oncotarget       Date:  2016-07-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.